A Florida State administrative judge ordered that levothyroxine sodium be taken off of the negative…
Read More
The ATA Unveils New Data to FDA On Bioequivalence of Levothyroxine Physician survey reveals significant…
ATA expresses concern to FDA regarding deletion of retitration warning after switching brands August 3,…
ATA writes letter to follow-up after FDA workshop June 30, 2005 Steven Galson, M.D. Director,…
Joint Public Meeting on Equivalence of Levothyroxine Sodium Products – Agenda Download Agenda (PDF File,…
FDA workshop on bioequivalence co-sponsored by the ATA, The Endocrine Society, and AACE [Federal Register:…
AACE, TES, and ATA Joint Position Statement on the Use and Interchangeability of Thyroxine Products…
Thyroid Experts Warn of Clinically Important Differences in Potency of FDA-Approved Levothyroxine Products Generic bioequivalence…
Thyroid Experts Speak Out Against the FDA’s Decision to Approve Generic Levothyroxine Preparations FDA approval…
ATA, TES, and AACE express disappointment and concern for the health of millions of thyroid…
AMERICAN THYROID ASSOCIATION® , ATA® , THYROID® , CLINICAL THYROIDOLOGY® , and the distinctive circular logo are registered in the U.S. Patent and Trademark Office as trademarks of the American Thyroid Association® , Inc.